| Bioactivity | FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC50 of 80 nM in HeLa cells. FM19G11 modulates other signaling pathways, including mTOR and PI3K/Akt/eNOS, when the HIF-1α pathway is inactivated under normoxic conditions[1][2]. |
| Target | HIF-1α |
| Invitro | FM19G11 (30-300 nM) inhibits HIFα proteins in the HeLa cell lines[1].FM19G11 (500 nM) promotes oligodendrocyte differentiation under hypoxia[1].FM19G11 (300 nM; 3 days) suppresses the mRNA levels of O6-methylguanine DNA-methyltransferase (MGMT) significantly in hypoxic GBM‐XD, hypoxic T98G, and normoxic T98G cells[2].M19G11 (300 nM; 3 days) significantly enhances the pro‐apoptotic effect of temozolomide (TMZ), although FM19G11 does not induce apoptosis by itself[2]. Cell Viability Assay[2] Cell Line: |
| In Vivo | FM19G11 ( intramedullary injection; 1-8 weeks) improves locomotion in severe spinal cord injury (SCI)[3].FM19G11 ( intramedullary injection; 8 weeks) induces the expression of GAP43, an axon growth marker, and RIP, a marker for myelinated oligodendrocytes at the injury[3]. |
| Name | FM19G11 |
| CAS | 329932-55-0 |
| Formula | C23H17N3O8 |
| Molar Mass | 463.40 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Victoria MM, et, al. FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status. J Biol Chem. 2010 Jan 8; 285(2): 1333-42. [2]. You CG, et, al. FM19G11 inhibits O 6 -methylguanine DNA-methyltransferase expression under both hypoxic and normoxic conditions. Cancer Med. 2018 May 15; 7(7): 3292-3300. [3]. Ana AA, et, al. FM19G11 and Ependymal Progenitor/Stem Cell Combinatory Treatment Enhances Neuronal Preservation and Oligodendrogenesis after Severe Spinal Cord Injury. Int J Mol Sci. 2018 Jan 9; 19(1): 200. |